Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for isolated coronary artery ectasia
IRCT20260212068837N1Phase 2Recruiting
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of apixaban, aspirin and atorvastatin in Coronary artery ectasia (CAE) (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Major adverse cardiac events, Major bleeding and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
apixabanaspirinatorvastatin
03
Conditions
Coronary artery ectasia (CAE)
Beyond the preview
Go deeper on IRCT20260212068837N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260212068837N1.